DJIA 18,001.10 288.44 1.63%
NASDAQ 4,942.89 51.67 1.06%
S&P 500 2,086.11 25.09 1.22%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

256.82 0.27 (0.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $256.82 0.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $256.58
Previous Close $256.56
Daily Range $256.46 - $257.36
52-Week Range $82.51 - $258.95
Market Cap $19.5B
P/E Ratio 233.23
Dividend (Yield) $0.00 (0.0%)
Volume 380,562
Average Daily Volume 2,307,066
Current FY EPS $0.26

Sector

Healthcare

Industry

Drug Makers

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary Rss Feed

Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?

AbbVie and Gilead are two closely followed dividend stocks in the healthcare sector. Which one offers investors the better long-term prospects moving forward?

Pharmacyclics, BioMarin, And Incyte: A Quick Screen

New ETF From BlackRock And Edelman

New ETF From BlackRock And Edelman

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Confessions of a Value Investor Stuck in a High-Growth Industry

It's OK to buy premium-priced biotechs.

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releas

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases

Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog

Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $256.82 (0.10%)
Current stock: PCYC
AMGN $163.76 (0.72%)
Current stock: AMGN
GILD $99.99 (-1.00%)
Current stock: GILD
BIIB $431.58 (0.40%)
Current stock: BIIB